BMRN: Pending Amicus Acquisition Will Recast Earnings Power Despite Treatment Franchise Uncertainty

Analysts have nudged their fair value estimate for BioMarin Pharmaceutical to $89.96, reflecting updated assumptions on discount rate, revenue growth, profit margins, and a higher future P/E following a mix of recent price target increases and reductions across the Street.

Analyst Commentary

Street research on BioMarin Pharmaceutical has been active, with a mix of higher and lower price targets and one recent coverage reinstatement at Goldman Sachs. Analysts are weighing the Voxzogo franchise, the planned Amicus acquisition, pipeline readouts and recent trial decisions when thinking about valuation and execution risk.

Bullish Takeaways

Bullish analysts see the planned Amicus acquisition and Voxzogo indication expansion as important contributors to BioMarin's potential value, and are updating their models to reflect these elements in long term growth assumptions.
Some bullish views highlight BioMarin's diversified product base, with comments that enzyme revenues look solid and that the broader story is becoming less dependent on Voxzogo alone.
Several research notes point to upcoming Phase 3 readouts and early stage data, such as BMN 351, as potential drivers that could increasingly influence how the stock is valued over time.
There is a camp that sees recent weakness tied to Voxzogo trial discontinuations and competitive concerns as an opportunity, arguing that the shares trade below what they view as the value of the business excluding Voxzogo.

Bearish Takeaways

Bearish analysts are cautious around the Voxzogo franchise, citing the discontinuation of some Phase 2 studies and a view that consensus expectations for long term Voxzogo growth may underappreciate future disruption.
Several target cuts reference more conservative assumptions for Voxzogo, including concerns about a potential once weekly injectable competitor and a possible once daily oral competitor, which they see as a risk for pricing power and patient adherence trends.
Some research argues that guidance tied to Voxzogo looks soft and that consensus may be too optimistic on the duration and size of the franchise tail, which feeds into lower valuation multiples in their models.
Even where ratings stay constructive, reduced targets from some bearish analysts reflect a view that Voxzogo and Roctavian related headwinds offset part of the upside they ascribe to the Amicus deal and other pipeline assets.

What’s in the News

Updated 2026 revenue guidance introduced, with the company outlining a total revenue range of US$3.33b to US$3.43b for the year. (Corporate guidance)
Subsequent revision to the 2026 outlook, with total revenues now guided to US$3.83b to US$3.93b, compared with the earlier range of US$3.33b to US$3.43b. (Corporate guidance)
VOXZOGO data from long term extension trials in children with achondroplasia reported, with treatment linked to changes in arm span and bone health measures and presentations planned at the Pediatric Endocrine Society 2026 Annual Meeting. (Product announcement)
Decision announced to stop dosing and enrollment in Phase 2 VOXZOGO trials for Turner Syndrome, SHOX deficiency and ACAN deficiency after slipped capital femoral epiphysis events in external investigator studies, while Phase 2 CANOPY trials in Noonan syndrome and idiopathic short stature continue. (Product announcement)
New VOXZOGO data in children with achondroplasia planned for presentation at the 2026 ACMG meeting, including outcomes in children starting treatment before age 2 and under 6 months, focused on growth, body proportionality and arm span versus untreated children. (Product announcement)
PALYNZIQ label expanded by the U.S. FDA to include pediatric patients 12 years and older with phenylketonuria, supported by Phase 3 PEGASUS data and accompanied by continued REMS requirements due to anaphylaxis risk. (Product announcement)

Valuation Changes

Fair Value: updated modestly from $88.87 to $89.96, reflecting small tweaks across key assumptions.
Discount Rate: nudged higher from 7.13% to 7.34%, implying a slightly higher required return on the stock.
Revenue Growth: adjusted slightly from 14.96% to 14.67%, pointing to a minor reset in long term sales expectations.
Net Profit Margin: reduced from 28.57% to 26.44%, indicating a more cautious stance on long run profitability.
Future P/E: raised from 15.08x to 16.95x, suggesting a higher multiple applied to the earnings outlook in the updated model.

9 views

Key Takeaways

Expanding global demand, new therapies, and strategic acquisitions strengthen BioMarin's revenue growth, market reach, and future pipeline potential.
Operational efficiency, disciplined cost management, and regulatory advantages support sustained profitability and long-term margin stability.
Revenue and earnings face mounting risks from escalating competition, pricing pressures, pipeline dependency, heightened expenses, and regulatory uncertainty across key products and markets.

Catalysts

About BioMarin Pharmaceutical

A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.What are the underlying business or industry changes driving this perspective?

Strong year-over-year revenue growth driven by increasing global demand, new patient starts, and international expansion of key therapies like VOXZOGO and VIMIZIM aligns with demographic shifts and improved rare disease diagnosis, supporting continued top-line revenue growth.
Accelerated pipeline advancement, including late-stage programs (BMN 333 for achondroplasia, BMN 401 for ENPP1 deficiency, and label expansions for PALYNZIQ), positions BioMarin to capitalize on growing patient pools through earlier and more accurate genetic identification, which should expand future addressable markets and boost revenue.
Recent acquisition of Inozyme and ongoing business development initiatives broaden BioMarin's enzyme therapy portfolio and introduce new high-value therapies targeting severe unmet needs, enhancing diversification and durability of revenue streams over the long term.
Company's operational leverage and disciplined cost management as new products move from R&D to commercial stage-combined with efforts to improve patient adherence and maximize market penetration-are likely to support margin expansion and drive earnings growth.
Supportive regulatory environment for orphan drugs, including accelerated pathways and favorable exclusivity, provides revenue protection and mitigates risks from generic/biosimilar competition, thereby underpinning long-term profitability and net margin stability.

BioMarin Pharmaceutical Earnings and Revenue Growth

BioMarin Pharmaceutical Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming BioMarin Pharmaceutical's revenue will grow by 14.7% annually over the next 3 years.
Analysts assume that profit margins will increase from 8.3% today to 26.4% in 3 years time.
Analysts expect earnings to reach $1.3 billion (and earnings per share of $6.6) by about May 2029, up from $268.7 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $2.1 billion in earnings, and the most bearish expecting $746.2 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 17.0x on those 2029 earnings, down from 38.3x today. This future PE is lower than the current PE for the US Biotechs industry at 17.2x.
Analysts expect the number of shares outstanding to grow by 0.78% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.34%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Intensifying competition in the rare disease and skeletal growth disorder market-such as the development of competing long-acting CNP therapies and potential combination treatments with growth hormone-may limit future revenue growth of BioMarin's key asset VOXZOGO and upcoming agents like BMN 333, raising risks of price erosion and reduced market share. (Likely impacts: revenue, net margins)
Ongoing and anticipated increases in R&D and SG&A expenses related to pipeline advancement, business development (e.g., Inozyme acquisition integration), and commercial expansion could compress operating margins and result in lower future earnings, especially if anticipated product approvals and launches are delayed or unsuccessful. (Likely impacts: net margins, earnings)
Secular pricing pressure and order timing outside the U.S. (noted in revised forward guidance), as well as the backdrop of global reimbursement reform and payer scrutiny for rare disease treatments, may weaken BioMarin's ability to achieve premium pricing and sustainable top-line growth. (Likely impacts: revenue, net margins)
Portfolio concentration risk remains elevated, with current and upcoming revenue disproportionately dependent on a limited number of products (VOXZOGO, PALYNZIQ, VIMIZIM); any issues such as loss of exclusivity, unfavorable intellectual property decisions (e.g., ongoing litigation/IPR&D review, orphan drug extension disputes), or failure to achieve regulatory milestones could result in abrupt revenue declines and higher volatility in earnings. (Likely impacts: revenue, earnings)
Regulatory risks-including the need for successful Phase II/III and pivotal trials, evolving requirements for functional and clinical endpoints (as seen for BMN 401/ENERGY III), and potential delays or negative outcomes in ongoing ITC proceedings, FDA reviews, and international submissions-may increase costs, delay market entry, or limit future approvals, thereby slowing prospective revenue and profit growth. (Likely impacts: revenue, net margins, earnings)

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $89.96 for BioMarin Pharmaceutical based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $120.0, and the most bearish reporting a price target of just $55.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $4.9 billion, earnings will come to $1.3 billion, and it would be trading on a PE ratio of 17.0x, assuming you use a discount rate of 7.3%.
Given the current share price of $53.24, the analyst price target of $89.96 is 40.8% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on BioMarin Pharmaceutical?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

BMRN: Revenue Guidance Revision Will Reveal New Competitive Dynamics Ahead